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INTRODUCTION
Nasal polyposis (NP) is one of the most common mass lesions of
the nose and was first described 4,000 yr ago in ancient Egypt.
The prevalence of NP is reported from 0.2% to 4.3% worldwide,
with a ratio of 2-3:1 between males and females (1). In children,
NP is relatively rare and has a close relationship with asthma and
cystic fibrosis (2). NP is a multifactorial condition which is often
associated with many diseases and pathogenic disorders, such as
allergy, infection, cystic fibrosis, asthma, and aspirin intolerance (1).
However, the underlying mechanisms interlinking these patho-
logic conditions to NP formation remain unclear. 
NPs are outgrowths of nasal mucosa which are smooth, semi-
translucent, gelatinous and pale. Histo-morphological character-
ization of polyp tissue reveals frequent epithelial damage, a thick-
ened basement membrane, and oedematous to sometimes fibrot-
ic stromal tissue, with a reduced number of vessels and glands, but
virtually no neural structure (3). Hellquist (4) divided NPs into
four histological patterns. The most common type was the ede-
matous NP with predominant eosinophilia, which constituted
85-90% of NPs. Other types include fibroinflammatory, hyper-
plasia of seromucinous glands and atypical stroma. It is not clear
whether this classification has an impact on the differentiation of
pathogenic mechanisms and clinical management of NPs. 
Although the mechanisms involved in the pathogenesis of NP
remain largely unclear, there are reports suggesting an underly-
ing genetic predisposition. This concept is supported by some clini-
cal data and genetic studies. This paper reviews recent understand-
ing of the pathogenic mechanisms of NPs, which are influenced
by a complex immune procedure including interaction of multi-
ple genes. This review paper does not include NP in cystic fibrosis
(CF), which is known to be a hereditary disease with multi-sys-
temic involvement with genetic variations, presenting with defect
in chloride transport across membranes and dehydrated secretions.
FAMILY AND TWIN STUDIES OF NPS
An interesting observation is that NP is frequently found to run
in families, suggesting a hereditary or shared environmental fac-
tor. In the study by Rugina et al. (5), more than half of 224 NP
patients (52%) had a positive family history of NP. The presence
of NP was considered when NP had been diagnosed by an ENT
practitioner or the patients had undergone sinus surgery for NP.
A lower percentage (14%) of familial occurrence of NP was report-
ed earlier by Greisner and Settipane (6) in a smaller group (n=50)
of adult patients with NP. Thus, these results strongly suggest the
existence of a hereditary factor in the pathogenesis of NP. 
However, studies of monozygotic twins have not shown that
Nasal polyposis (NP) is a common chronic inflammatory disease of the rhinosinus mucosa and a complex disease with strong
genetic and environmental components. During the past 10 to 20 yr, many studies have been performed to determine
differential gene expression profiles between NP and normal nasal tissues, in order to identify susceptible genes that are
associated with NP-related traits. Despite achievement in the identification of candidate genes and their associated path-
ogenic pathways, the large challenges remain as the genetic and molecular alterations required for its development and
progression are still unclear. Therefore, the development of novel, powerful tools for gene discovery, and a closer inte-
gration of genetics and medical biology would provide valuable insight into the pathogenesis of NP.
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Reviewboth siblings always develop polyps, indicating that environ-
mental factors are likely to influence the occurrence of NP (7, 8).
NPs have been described in identical twins, but given the preva-
lence of nasal polyps, it might be expected that there would be
more than a rare report of this finding (9).
LINKAGE ANALYSIS AND ASSOCIATION
STUDIES ASSOCIATED WITH NPS
In the literature, some studies were able to show linkage of cer-
tain phenotypes of NP to candidate gene polymorphisms. Karj-
alainen et al. (10) reported that subjects with a single G-to-T poly-
morphism in exon 5 at +4,845 of the gene encoding IL-1alpha
(IL-1A) were found to have lower risk of developing NP as com-
pared to subjects with common G/G genotype. In another study,
polymorphism of IL-4 (IL-4/-590 C-T), a potential determinant
of IgE mediated allergic disease, was also found to be associated
with a protective mechanism against NPs in the Korean popula-
tions (11). Recently, another asthma-related Argl6gly polymor-
phism of the beta2-adrenoceptor gene (ADRBeta2) was found
to be associated with an increased risk of NP (12).
A number of genetic association studies found a significant cor-
relation between certain human leukocyte antigen (HLA) alleles
and NP. HLA is the general name of a group of genes in the human
major histocompatibility complex (MHC) region on the human
chromosome 6 that encodes the cell-surface antigen-presenting
proteins. Luxenberger et al. (13) reported an association between
HLA-A74 and NPs, whereas Molnar-Gabor et al. (14) reported
that subjects carrying HLA-DR7-DQA1*0201 and HLA-DR7-
DQB1*0202 haplotype had a 2 to 3 times odds ratio of devel-
oping NP. The risk of developing NP can be as high as 5.53 times
in subjects with HLA-DQA1*0201-DQB1*0201 haplotype (15).
Although several HLA alleles were found to be associated with
NP, such susceptibility can be influenced by ethnicity. In the Mexican
Mestizo population, increased frequency of the HLA-DRB1*03
allele and of the HLA-DRB1*04 allele were found in patients with
NP as compared to healthy controls (16).
MULTIPLE GENE EXPRESSIONS IN NASAL
POLYPS
The development and persistence of mucosal inflammation in NPs
have been reported to be associated with numerous genes and
potential single nucleotide polymorphisms (SNPs). The products
of these genes determine various disease processes, such as immune
modulation or immuno-pathogenesis, inflammatory cells (e.g.,
lymphocytes, eosinophils and neutrophils) development, activa-
tion, migration and life span, adhesion molecule expression, cyto-
kine synthesis, cell-surface receptor display, and processes gov-
erning fibrosis and epithelial remodelling.
Gene profiling technologies have demonstrated considerable
power in generation of cell and tissue molecular signatures and
identification of disease-associated gene expression changes, and
represent a rapid and efficient mean to elucidate alterations in
cell signalling or metabolic pathways. DNA microarray technol-
ogy consists of a matrix with attached sequences that allow simul-
taneous analysis of expression of panels of human genes. Com-
parison of profiles of genes expressed in disease versus healthy
tissues often highlights the involvement of both expected and unsus-
pected pathologic pathways. 
In the literature, gene expression profiles in NPs have been
performed by many studies, including the major repertoire of
disease-related susceptibility genes or genotypic markers. With
the advance of microassay technique, expression profiles of over
10,000 of known and novel genes can be detected. A recent study
showed that in NP tissues, 192 genes were upregulated by at least
2-fold, and 156 genes were downregulated by at least 50% in
NP tissues as compared to sphenoid sinuses mucosa (17). In anoth-
er study (18), microarray analysis was used to investigate the
expression profile of 491 immune-associated genes in NPs. The
results showed that 87 genes were differentially expressed in
the immune-associated gene profile of nasal polyps, and 15 genes
showed differential expression in both NPs and healthy controls
(turbinates). In other studies, alterations in expression profiles of
susceptible genes may contribute to many putative underlying
pathophysiological or pathogenic mechanisms of NPs.
Genes associated with inflammation and immunopatho-
genesis in NPs
NP is a chronic inflammatory disease of the mucous membranes
in the nose and paranasal sinuses. The role of the immune system
in the pathogenesis of this disease is still unknown. To date, many
studies have reported significant changes in presence of numer-
ous inflammatory cells, mediators, cytokines, chemokines, and
other inflammatory and immune modulating components in NPs,
indicating that chronic inflammation is an important factor in devel-
opment of NPs irrespective of the etiology.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is charac-
terized by a T(H)2-skewed eosinophilic inflammation, whereas
chronic rhinosinusitis without nasal polyps (CRSsNP) represents
a predominant T(H)1 milieu (18). In this report, the authors were
able to show a significantly lower forkhead box P3 (FOXP3) mRNA
and transforming growth factor beta-1 (TGF-beta1) protein expres-
sion, but a significantly higher T-bet, GATA-3, IL-5, and IL-13
mRNA expression compared with the healthy controls (Table
1). This T(H)2-skewed eosinophilic inflammation was shown by
a decreased expression of multiple antimicrobial innate immune
markers, including toll-like receptor 9, human beta- defensin 2 and
surfactant protein A, in human sinonasal epithelial cells from
CRSwNP. The authors suggested that the impaired mucosal
innate immunity may contribute to microbial colonization (e.g.,
bacteria, fungi and etc.) and abnormal immune responses associat-
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sion level of complement component C1q in NPs is suggested
to be indicative of an ongoing inflammatory response in the
nasal mucosa of these patients (21).
Innate immune recognition of pathogens by sinonasal epithe-
lial cells may play an important role in the pathogenesis of chron-
ic mucosal inflammation in rhinosinusitis (CRS) (22, 23). In Table
1, alterations in expression levels of several genes associated with
immunopathogenesis in nasal mucosal or NP tissues are indica-
tives of an ongoing inflammation and impaired mucosal innate
immunity in patients with CRS with or without NPs.
Biological functions of inflammatory cells in NPs
The general histopathological classification of NPs is eosinophil-
dominated inflammation (80-90%), which appears to be a hall-
mark of Caucasian NPs (3). This statement is well supported by
an increased expression of cytokines, chemokines and molecu-
lar markers, which are involved in the proliferation, migration,
activation and survival of eosinophils (Table 2). In the literature,
IL-5 and eotaxin are most frequently reported molecular mark-
ers in NPs, as they are essential for eosinophil development, acti-
vation and survival (3). The soluble IL-5Rαexpression level was
also found to be dramatically higher (up to 1,200 times) than IL-
5 concentrations in NP (37). 
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Table 1. Expression profile of genes associated with inflammation and immunopathogenesis in nasal polyposis
Pathogenic pathway Name of genes Potential biological/immunologic functions
Table 2. Expression profile of genes associated with the biological functions of inflammatory cells in nasal polyposis
High/ Ragulated upon activation, normal T expressed and secreted (41, 42, 43) Eosinophil recruitment
overexpressed IL-5 (44, 45, 46) Biological functions of eosinophils
Aquaporin-1 (47) Survival of eosinophils
Protein kinase C (48) Apoptosis inhibition (eosinophils)
Eotaxin (42, 49, 50) Enhance self-amplification process (eosinophils)
Growth-related oncogene-alpha (51) Recruitment and activation of neutrophils
Stem cell factor (52) Master cell growth and survival factor
C-C Chemokine ligand 2 (53) Recruitment of macrophages
Regulator of G-protein signaling 1 (54) Cell signal transduction
IL-8 (54) Releasing inflammatory factors
Survivin (55) Cell apoptosis
High/overexpressed IL-17 and IL-17 receptor (18) Proinflammatory cytokine 
Lysophosphatidic acid receptor (24) Inflammatory cascade
LL-37 (25) Antimicrobial peptide
Superoxide dismutases gene SOD3 and SOD1 (26) Increased oxidative stress
Human beta-defensin-2 (27) A key element in the innate host defence mechanism
Cyclooxygenase-1 (28) Mucosal inflammation
CD40 (29) Regulation of inflammation 
IL-1 beta, IL-6, IL-8, and transforming growth factor beta (30) Pathogenesis of NP (non-allergic pattern of inflammation)
Granulocyte macrophage colony-stimulating factor Local tissue inflammation
and IL-8 (31)
Tumor necrosis factor alpha (32) Pro-inflammatory activity (in particular with eosinophils)
T-box transcription factor (T-bet) (19) Transcription factors for T-cell subpopulations
GATA-3 (19) Transcription factors for T-cell subpopulations
Complement component C1q (21) Innate immunity
Low/underexpressed Cyclooxygenase-2 (28, 33) Mucosal inflammation
Syk (34, 35) Intracellular signal transduction in hemopoietic cells
Forkhead box P3 (FOXP3) (19) Transcription factors for T-cell subpopulations
Toll-like receptor 9 (20) Mucosal innate immunity
Human beta-defensin 2 (20) Mucosal innate immunity
Surfactant protein A (20) Mucosal innate immunity
B-Raf and Raf kinase inhibitor protein (36) Endogenous inhibitors of the MAPK pathway
Toll-like receptor 9 (22) Impaired innate immunityIn addition, infiltration of other types of inflammatory cells,
especially lymphocytes and neutrophils, may also play an impor-
tant role in the inflammatory process underlying the pathogen-
esis of NPs (38-40). In Table 2, increased expression levels of
growth-related oncogene-alpha (GRO-alpha), stem cell factors
(SCF) and C-C chemokine ligand 2 are associated with biologi-
cal functions of neutrophils, mast cells and macrophages. Therefore,
in NP studies, one may not rely solely on limited type of cells and
number of molecular markers (e., g., IL-5 and eotaxin) as NP is
a heterogeneous disease with complex pathogenic mechanisms
involved.
Genes associated with structure modification of
epithelium in NPs
Histomorphological characterisation of NP tissue reveals frequent
epithelial damage, a thickened membrane, and oedematous to
sometimes fibrotic stromal tissue, with a reduced number of ves-
sels and glands, but virtually no neutral structure (3). Many genet-
ic studies have resulted in an emphasis on the structure modifi-
cation of the epithelium in NPs. Table 3 shows the changes in
expression level of many important genes, which are associated
with proliferations of nasal epithelial and endothelial cells, sub-
mucosal glandular cells, regulation of goblet cell mucins, tissue
remodelling, angiogenesis, impaired electrolyte and water trans-
port across the epithelial cells, epithelial barrier maintenance and
repair, and etc. However, pathogenic mechanisms underlying the
changes of these structural gene functions are not clear.
There are a number of genes which are involved in epithelial
barrier maintenance and repair in the inflammatory state of chron-
ic rhinosinusitis (CRS) with NPs. For example, carbonic anhydrase
(CA) is a zinc metalloenzyme that participate in the biological
processes of various fluid transporting epithelia, including ion and
water transport. In this study, a decreased expression level of CA
was found to be associated with impaired electrolyte and water
transport across the epithelial cell, which will result in oedema
of NP tissue (56). In another study, the level of epidermal growth
factor receptor (EGFR) mRNA in human sinus mucosa was found
to be statistically significantly increased compared with that in
the healthy controls (57). It is therefore suggested by the authors
that up-regulation of the EGFR cascade may have an important
role regarding mucus production in the sinus mucosa of patients
with CRS and CRS with NP associated with hyperplasia and meta-
plasia of epithelial goblet cells.
Epithelial differential and tissue remodelling is also reported
to be involved in the development and pathogenic characteriza-
tion of NPs. It was reported that an increased expression level of
PDGF-B, TGF-beta1, and lower expressions of lumican and bigly-
can were found in NPs as compared to the healthy controls (Table
3). However, controversial results of TGF-beta1 expression level
were also reported by other studies, where the expression levels
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Table 3. Expression profile of genes associated with structure modification of epithelium in nasal polyposis
High/overexpressed Hepatocyte growth factor and c-Met proteins (58) Enhancing proliferation of epithelial cells and 
submucosal glandular cells
Proliferation cell nuclear anttigen, apoptosis associate Proliferation activity in the epithelium
gene protein (Bcl-2 and Bax) (59)
Basic fibroblast growth factor (60) Endothelial and epithelial proliferation
Keratinocyte growth factor (61) Nasal epithelial proliferation
P53 (62) Epithelial proliferation activity
Mucin 1, MUC4, MUC5AC, MUC5B (63-68) Polyp formation and progression
Epidermal growth factor receptor (57, 69) Regulation of goblet cell mucins
Fas-L protein (70) Cystic degeneration of submucosal glands
Vascular permeability factor and vascular endothelial Development of oedema in chronic inflammation
growth factor (71)
Platelet-derived growth factor-B chain (72) Chronic inflammation and tissue remodelling
Vascular endothelial growth factor A (73) Angiogenesis
Transforming growth factor beta1 (73) Epithelial differentiation and tissue remodelling
Insulin-like growth factor 1 (73) Angiogenesis
Fibroblast growth factor 2 (73) Angiogenesis?
Matrix metalloproteinase-9 (44) Zn2+ dependent endopeptidases. Degradation
extracellular matrix and tissue edema
Low/underexpressed Lumican and biglycan (74) Remodelling of the extracellular matrix
Carbonic anhydrase isoenzymes (56) Impaired electrolyte and water transport across
the epithelial cells
S100A7, S100A8, S100A7 (75) Epithelial barrier maintenance and repair
Serine protease inhibitor kazal type 5 (75) Epithelial barrier maintenance and repair
Transforming growth factor beta1 (19, 76, 77) Chemoattractant and proliferation factor for fibroblastsof TGF-beta1 in NPs appeared to be low in NPs (Table 3).
Significant genes with other or unclear biological
functions in NPs
Using a genome-wide expression microarray, some studies have
reported a few genes with significant changes in expression pro-
files in NP tissue as compared to healthy controls (Table 4). How-
ever, the biological functions of some of these genes (e.g., plas-
ma membrane intrinsic protein [PIP], deleted in malignant
brain tumors 1 [DMBT1], Mammaglobin and CC10) underlying
the pathogenic mechanisms of NP development are unclear and
need to be investigated in future.
Mutation and differential expression of the ras family genes
contributing to tumourigenesis either through the accumulation
of mutations or by aberrant expression in a wide range of human
cancers has been well demonstrated. However, a recent study
found that K- and H-ras expression levels were elevated, where-
as N-ras mRNA levels were lower in NPs and adjacent turbinates
as compared to the healthy control tissues. K-ras mRNA levels
were up-regulated in advanced-stage polyps, while N-ras levels
were found elevated in small polyps (78). These findings suggest
a potential key role for activated members of ras family genes
in terms of their contribution to the development of NPs as well
as to the hypertrophy of adjacent turbinates.
The presence of aspiring-intolerance in a patient with CRS with
or without NPs is associated with a particularly persistent and
treatment-resistant form of disease, coexisting usually with severe
asthma and referred to as the “aspiring triad” (3). In a recent study,
genome-wide expression microarray study was performed in 57
patients with three distinct phenotypes: 1) patients with chronic
rhinosinusitis and sinonasal polyposis without a history of aspirin
allergy (CRS group); 2) patients with chronic rhinosinusitis and
sinonasal polyposis with a history of asthma and aspirin allergy
(ASA group); and 3) patients with no history or clinical evidence
of sinusitis, asthma, or aspirin allergy (control group) (79). This
study was able to identify five genes (POSTN, MET, PIP, AZGP1,
and PPP1R9B) that are likely to play a role in the pathogenesis
of sinonasal polyps associated with CRS and ASA (Table 4).
CONCLUSION
The expression of gene products is regulated at multiple levels,
such as during transcription, mRNA processing, translation, phos-
phorylation and degradation. Although some studies were able
to show certain NP associated polymorphisms and genotypes,
the present data is still fragmented. Same as for many common
human diseases, inherited genetic variation appears to be criti-
cal but yet still largely unexplained. Future studies are needed
to identify the key genes underlying the development or forma-
tion of NP and to investigate the interactions between genetic
and environmental factors that influence the complex traits of
this disease. Identifying the causal genes and variants in NP is
important to the path towards improved prevention, diagnosis
and treatment of NPs. 
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